Mer­ck KGaA draws the cur­tain on newest lipid nanopar­ti­cle for mR­NA vac­cines, tur­bocharg­ing its an­nu­al ca­pac­i­ty

With the mir­a­cle of mR­NA vac­cines turn­ing the tide on the pan­dem­ic, the spot­light has shift­ed to tiny en­gi­neered fat bub­bles, dubbed lipid nanopar­ti­cles, that shut­tle those drugs in­to pa­tients’ im­mune cells. Ger­many’s Mer­ck KGaA, look­ing to cor­ner de­mand for the much-in-need de­liv­ery tool is now rolling out a high­er-ef­fi­cien­cy ver­sion months ahead of sched­ule.

Mer­ck KGaA on Wednes­day un­veiled a new syn­thet­ic cho­les­terol prod­uct for launch, which it said will in­crease ca­pac­i­ty for its lipid de­liv­ery tools by 50 times, ac­cord­ing to a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER